Read by QxMD icon Read

Journal of Nuclear Medicine

Anni Gålne, Helen Almquist, Martin Almquist, Cecilia Hindorf, Tomas Ohlsson, Erik Nordenström, Anna Sundlöv, Elin Trägårdh
Rationale: Patients with neuroendocrine tumors (NETs) are often treated with somatostatin analogs for control of symptoms and tumor growth. Such therapy could theoretically lead to misinterpretation of somatostatin receptor imaging with 68 Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) by interfering with tracer-receptor binding. Guidelines recommend an interval of 3-4 weeks between the last dose and imaging. The aim of this study was to evaluate if long-acting somatostatin analog (LA-SSA) treatment changes the uptake of 68 Ga-DOTATATE in patients with NETs...
April 18, 2019: Journal of Nuclear Medicine
Bernard H E Jansen, Maqsood Yaqub, Jens Voortman, Matthijs C F Cysouw, Albert D Windhorst, Robert C Schuit, Gerbrand M Kramer, Alfons J M van den Eertwegh, Lothar A Schwarte, Harry N Hendrikse, André N Vis, Reindert J A van Moorselaar, Otto S Hoekstra, Ronald Boellaard, Daniela E Oprea-Lager
Radiolabeled Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) has demonstrated promising results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer uptake is desired as it enables reliable interpretation of PET-images, the use of PSMA uptake as an imaging biomarker for tumor characterization, and evaluation of treatment effects. The aim of this study was to perform a full pharmacokinetic analysis of 18 F-DCFPyL, a second generation 18 F-labeled PSMA ligand. Based on the pharmacokinetic analysis (reference method), simplified methods for quantification of 18 F-DCFPyL uptake were validated...
April 18, 2019: Journal of Nuclear Medicine
Ahmadreza Rezaei, Georg Schramm, Stefanie Ma Willekens, Gaspar Delso, Koen Van Laere, Johan Nuyts
Time of flight (TOF) positron emission tomography (PET) data provide an effective means for attenuation correction (AC) when no (or incomplete/inaccurate) attenuation information is available. Since magnetic resonance (MR) scanners provide little information on photon attenuation of different tissue types, AC in hybrid PET/MR scanners has always been challenging. In this contribution, we aim at validating the activity reconstructions of the maximum likelihood activity and attenuation reconstruction (MLAA) algorithm on a patient brain dataset...
April 12, 2019: Journal of Nuclear Medicine
Olivier Martinez, Jane K Sosabowski, John Maher, Sophie Papa
Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell based therapies, with or without genetic modification ex vivo, have reached the clinic as standard of care in limited indications and remain the subject of intense pre-clinical and translational development. Expanding on this, related therapeutic approaches are in development for solid tumor and non-malignant indications, broadening the scope of this technology. It has long been recognized that in vivo tracking of infused cellular therapies would provide unique opportunities to optimize their efficacy and aid in the assessment and management of toxicity...
April 12, 2019: Journal of Nuclear Medicine
Valtteri Kaasinen, Tuomas Kankare, Juho Joutsa, Tero Vahlberg
Background: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) have overlapping signs and symptoms with Parkinson's disease (PD), and these similarities complicate their clinical diagnostics. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS and PD using combined quantitative data from all published studies...
April 12, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Etienne Rousseau, Don Wilson, Frédéric Lacroix-Poisson, Andra Krauze, Kim Chi, Martin Gleave, Michael McKenzie, Scott Tyldesley, S Larry Goldenberg, François Bénard
18 F-DCFPyL, a prostate specific membrane antigen targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity and impact on patient management of 18 F-DCFPyL in the settings of biochemical recurrence of prostate cancer. Methods: Subjects with prostate cancer and biochemical recurrence post radical prostatectomy/curative intent radiotherapy were included in this prospective study. The subjects underwent 18 F-DCFPyL PET/CT imaging. The localisation and number of lesions were recorded...
April 12, 2019: Journal of Nuclear Medicine
Maike E Lindemann, Nika Guberina, Axel Wetter, Wolfgang Fendler, Bjoern Jakoby, Harald H Quick
Purpose: A limitation of using 68-gallium-labelled prostate-specific membrane antigen (68-Ga-PSMA) for detection and staging of prostate cancer is a frequently observed halo artifact around the urinary bladder caused by inaccurate scatter correction (SC) of positron emission tomography (PET) data. The aim of this study is to investigate the impact of un-renormalized absolute SC on 68-Ga-PSMA PET quantification in PET/magnetic resonance (MR) hybrid imaging of the prostate in 100 patients. Methods: The PET data of 100 patients were reconstructed twice using standard SC and improved un-renormalized SC...
April 12, 2019: Journal of Nuclear Medicine
Michael M Graham, John M Buatti
No abstract text is available yet for this article.
April 6, 2019: Journal of Nuclear Medicine
Sally F Barrington, Michel A Meignan
Increased tumour burden is associated with inferior outcomes in many lymphoma subtypes. Surrogates of tumour burden that are easy to measure, such as the maximum tumour dimension of the 'bulkiest' lesion on CT have been used as prognostic indices for many years. Recently, the total metabolically (active) tumour volume (M(A)TV) and tumour lesion glycolysis (TLG) have emerged as promising and robust biomarkers of outcome in various lymphomas. The median MTV value and the optimal cut-off points to separate patients into risk groups in a study population are however, highly dependent on the population characteristics and the delineation method used to outline tumour in the PET image...
April 6, 2019: Journal of Nuclear Medicine
Mary-Ann Elvina Xavier, Shihui Liu, Thomas H Bugge, Julia Baguna-Torres, Michael Mosley, Samantha Lake Hopkins, Phillip Danny Allen, Georgina Berridge, Iolanda Vendrell, Roman Fisher, Veerle Kersemans, Sean Smart, Stephen H Leppla, Bart Cornelissen
Purpose: Increased activity of matrix metalloproteinases (MMPs) is associated with worse prognosis in different cancer types. The protective antigen (PA-WT) of the binary anthrax lethal toxin was modified to form a pore in cell membranes only when cleaved by MMPs (PA-L1). Anthrax lethal factor (LF) is then able to translocate through these pores. Here, we used an 111 In-radiolabelled form of LF with the PA/LF system for non-invasive in vivo imaging of MMP activity in tumour tissue by single photon emission computed tomography (SPECT)...
April 6, 2019: Journal of Nuclear Medicine
Eric Christopher Ehman, Mohamed Samir El-Sady, Marie Foley Kijewski, Yiu Ming Khor, Sophia Jacob, Frederick L Ruberg, Vaishali Sanchorawala, Heather Landau, Andrew Jenho Yee, Giada Bianchi, Marcelo F Di Carli, Rodney H Falk, Hyewon Hyun, Sharmila Dorbala
Immunoglobulin light chain amyloidosis (AL) affects multiple systemic organs. However, determination of the precise extent of organ involvement remains challenging. Targeted amyloid imaging with 18 F-florbetapir PET/CT offers the potential to detect AL amyloid deposits in multiple organs. The primary aim of this study was to determine the distribution and frequency of AL amyloid deposits in the various organs of subjects with systemic AL amyloidosis using 18 F-florbetapir PET/CT. Methods: This prospective study included 40 subjects with biopsy proven AL amyloidosis including active AL amyloidosis ( n = 30) or AL amyloidosis in hematological remission for >1 year ( n = 10)...
April 6, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Sandra van der Velden, Manon N G J A Braat, Tim A Labeur, Mike V Scholten, Otto M van Delden, Roelof J Bennink, Hugo W A M de Jong, Marnix G E H Lam
Purpose: Radioembolization is increasingly used as a bridge to resection (i.e. radiation lobectomy). It combines ipsilateral tumor control with the induction of contralateral hypertrophy to facilitate lobar resection. The aim of this pilot study was to investigate the complementary value of hepatobiliary scintigraphy (HBS) before and after radioembolization in the assessment of the future remnant liver. Methods: Consecutive patients with liver tumors who underwent HBS before and after yttrium-90 (90 Y) radioembolization were included...
April 6, 2019: Journal of Nuclear Medicine
Joseph J Grudzinski, Reinier Hernandez, Ian Marsh, Ravi Patel, Eduardo Aluicio-Sarduy, Jon Engle, Zachary Morris, Bryan Bednarz, Jamey P Weichert
We characterize the in vivo biodistribution and tumor selectivity of 86 Y-NM600, a theranostic alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of preclinical cancer models. Methods: Mice bearing flank tumors (representative of lung, pancreatic, prostate, liver, skin, and lymphoid cancers) were injected intravenously (IV) with 9.25 MBq of 86 Y-NM600 and imaged longitudinally over 4-5 days using microPET/CT. Percent injected activity per gram (%IA/g) for each volume-of-interest (VOI) was measured at each time point for the organs of interest...
April 6, 2019: Journal of Nuclear Medicine
Olayinka A Abiodun-Ojo, Akinyemi A Akintayo, Oladunni O Akin-Akintayo, Funmilayo I Tade, Peter T Nieh, Viraj A Master, Mehrdad Alemozaffar, Adeboye O Osunkoya, Mark M Goodman, Baowei Fei, David M Schuster
We evaluated 18 F-fluciclovine uptake parameters that correlate with true positivity for local recurrence in non-prostatectomy treated patients. Methods: Twenty-one patients (prostate-specific antigen 7.4±6.8 ng/ml) with biochemical recurrence after non-prostatectomy local therapy (radiotherapy and cryotherapy) had dual time-point 18 F-fluciclovine (364.1±37.7 MBq) positron emission tomography (PET)/computed tomography from pelvis to diaphragm. Prostatic uptake over background was delineated and co-registered to a prostate biopsy planning ultrasound...
April 6, 2019: Journal of Nuclear Medicine
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sabastian Adeberg, Hendrik Rathke, Manuel Roehrich, Hauke Winter, Peter Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn, Frederik Giesel
The recent development of quinoline based positron-emission-tomography (PET)-tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer associated fibroblasts (CAFs) of several tumor entities. Here we quantify the tumor-uptake in FAPI-PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: FAPI-PET/CTs were requested by various referring physicians according to individual clinical indications which were considered insufficiently covered by FDG-PET/CT or other imaging modalities...
April 6, 2019: Journal of Nuclear Medicine
Javier Gomez, Rami Doukky
No abstract text is available yet for this article.
March 29, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Hanna Cho, Jae Yong Choi, Hye Sun Lee, Jae-Hoon Lee, Young Hoon Ryu, Myung Sik Lee, Clifford R Jack, Chul Hyoung Lyoo
Background: Tau positron emission tomography (PET) enabled in vivo visualization and quantitation of tau pathology in Alzheimer disease (AD). In cross-sectional tau PET studies, tau burden reflected disease severity and phenotypic variation. We investigated longitudinal change in cortical tau accumulation and its associations with cognitive decline in patients with Alzheimer disease (AD). Methods: We enrolled 107 participants [45 amyloid β (Aβ)-negative cognitively unimpaired (CU-), 7 Aβ-positive cognitively unimpaired (CU+), 31 prodromal AD (mild cognitive impairment; MCI+), and 24 AD dementia (DEM+)] who completed two baseline PET scans (18 F-flortaucipir and 18 F-florbetaben), magnetic resonance imaging, and neuropsychological tests...
March 29, 2019: Journal of Nuclear Medicine
Charlotte Andersson, Emman Shubbar, Emil Schüler, Bo Åkersson, Magnus Gram, Eva Forssell-Aronsson
Treatment of neuroendocrine tumors (NETs) with 177 Lu-octreotate results in prolonged survival and improved quality of life for the patient. However, the treatment is today limited by side effects on kidney and bone marrow and complete tumor remission is rarely seen. A possible way to minimize dose-limiting toxicity and to optimize this treatment method is to use radio-protectors in conjunction with radiotherapy. A recombinant form of alpha-1-microglobulin (rA1M) was recently shown to preserve kidney structure and function after 177 Lu-octreotate injection in mice, and suggested as a radioprotector in Peptide Receptor Radionuclide Therapy...
March 29, 2019: Journal of Nuclear Medicine
Hossein Jadvar, Erik Velez, Bhushan Desai, Lingyun Ji, Patrick M Colletti, David I Quinn
The aim of this prospective investigation was to assess the association of 18 F-FDG PET/CT with time to hormonal treatment failure (THTF) in men with metastatic castrate-sensitive prostate cancer (mCSPC). Methods: 76 men with mCSPC recruited from 2005-2011 underwent 18 F-FDG PET/CT and were followed prospectively for THTF, defined as treatment change to chemotherapy or death. Patients who had not switched to chemotherapy were censored at the last follow-up date (median of 36 months, range 12-108 months). Cox regression analyses were performed to examine the association between PET/CT measurements: sum of SUVmax , maximum of SUVmax , and average of SUVmax of up to 10 of the most active lesions and THTF...
March 29, 2019: Journal of Nuclear Medicine
Kambiz Rahbar, Michael S Hofman, Andres J Schrader, Martin Boegemann
No abstract text is available yet for this article.
March 29, 2019: Journal of Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"